公司概覽
業務類別 Biotechnology
業務概覽 Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
公司地址 12390 El Camino Real, San Diego, CA, USA, 92130
電話號碼 +1 858 794-8889
傳真號碼 +1 858 704-8311
公司網頁 https://www.halozyme.com
員工數量 423
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Cortney Caudill Senior Vice President and Chief Operating Officer -- 17/02/2026
Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B. Director, President and Chief Executive Officer 美元 960.00K 17/02/2026
Mr. Mark Snyder Senior Vice President, General Counsel, Chief Compliance Officer and Secretary 美元 579.00K 17/02/2026
Ms. Nicole LaBrosse Senior Vice President, Chief Financial Officer and Principal Accounting Officer 美元 568.19K 17/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. James Lang Director 17/02/2026
Mr. Jeffrey W. Henderson Chairman of the Board 17/02/2026
Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B. Director, President and Chief Executive Officer 17/02/2026
Mr. Matthew L. Posard Independent Director 17/02/2026
Ms. Bernadette M. Connaughton Independent Director 17/02/2026
Ms. Barbara G. Duncan Independent Director 17/02/2026
Ms. Moni Miyashita Independent Director 17/02/2026
Dr. Mahesh Krishnan, M.B.A. Independent Director 17/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:25)
代號 名稱 佔比% 持有日期
GGZGabelli Global Small & Mid Cap Value Tru0.003%31/12/2025
DEUSXtrackers Russell US Multifactor ETF0.002%26/02/2026
JMIDJanus Henderson Mid Cap Growth Alpha ETF0.002%27/02/2026
FLOWGlobal X U.S. Cash Flow Kings 100 ETF0.002%27/02/2026
SXQGETC 6 Meridian Quality Growth ETF0.002%27/02/2026
DXUVDimensional US Vector Equity ETF0.002%27/02/2026
GGUSGoldman Sachs MktBt Russell LgCpGrEqETF0.002%27/02/2026
MIDUDirexion Daily Mid Cap Bull 3X ETF0.002%26/02/2026
MKTNFederated Hermes MDT Market Neutral ETF0.002%28/02/2026
CVLCCalvert US Large-Cp Cor Rspnb ETF0.001%27/02/2026
LRNDNYLI U.S. Large Cap R&D Leaders ETF0.001%27/02/2026
LSEQHarbor Long-Short Equity ETF0.001%28/02/2026
RUSCRussell Inv U.S. Small Cap Equity ETF0.001%28/02/2026
JHMLJHancock Multifactor Large Cap ETF0.001%27/02/2026
FNDBSchwab Fundamental U.S. Broad Market ETF0.001%28/02/2026
CVMCCalvert US Mid-Cp Cor Rspnb ETF0.001%27/02/2026
SFYXSoFi Next 500 ETF0.001%19/02/2026
UMDDProShares UltraPro MidCap4000.001%27/02/2026
VLUState Street® SPDR® S&P® 1500 ValTiltETF0.001%27/02/2026
ONEOStt Strt® SPDR® Russell 1000 Momt FocETF0.0005%27/02/2026
  1    2    3    4    5    6   7    8    9    10    11  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.